BSX vs. ABT: Which MedTech Stock is the Better Investment Now?

Key Takeaways ABT appears more attractive on valuation and recent performance in this MedTech comparison.BSX posted 14% Q4 operational sales growth, with strength in EP, WATCHMAN and oncology.Abbott saw strong CGM sales above $7.5B in 2025 and expanded via the Exact Sciences deal.Among large-cap U.S. MedTech companies, Boston Scientific (BSX) and Abbott (ABT) continue to attract significant investor focus. Abbott’s business model is diversified, having leading businesses and products in diagnostics, medical ...